Wu Bin-Nan, Lin Hui-Li, Su Huey-Jen, Cheng Pei-Wen, Chen Ya-Mei, Hao Chi-Long, Shen Kuo-Ping
Department of Pharmacology, Graduate Institute of Medicine, College of Medicine, Drug Development and Value Creation Research Center, Kaohsiung Medical University.
Department of Medical Research, Kaohsiung Medical University Hospital.
J Nutr Sci Vitaminol (Tokyo). 2025;71(4):321-330. doi: 10.3177/jnsv.71.321.
This animal experiment aimed to evaluate the efficacy of the extract of pre-germinated brown rice (EP) and γ-oryzanol on non-alcoholic fatty liver disease (NAFLD) and the cardiac complications associated with it. WKY rats were fed high-fructose water (HFW) and high-fat diet (HFD) for 4 wk to induce NAFLD. The other two groups were fed HFW and HFD, while oral administration of EP 200 μL/kg or γ-oryzanol 2 mg/kg every day for 4 wk. NAFLD was successfully induced in as evidenced by clear increases in body, hepatic and cardiac weight as well as by increases in blood pressure and heart rate, hypertriglyceridemia, hyperuricemia, higher liver function index: glutamic pyruvic transaminase (GPT), higher levels of IL-6 and TNF-α in the blood and higher levels TG in the liver. NAFLD rats also had adverse changes the protein expressions of lipid synthesis, inflammation, cardiac fibrosis and hypertrophy. However, when the NAFLD rats were simultaneously fed EP or γ-oryzanol, the development of adverse diet-induced effects, including glutamic oxaloacetic transaminase (GOT), were clearly ameliorated. Specifically, EP could reduce uric acid levels, while γ-oryzanol did not. EP, as well as γ-oryzanol, reversed the increases in levels of lipid synthesis, inflammation, cardiac fibrosis and hypertrophy. We concluded that EP effectively prevented HFW/HFD-induced NAFLD and its associated cardiac complications, which it likely achieved through an improvement of lipid homeostasis and inhibition of inflammation. We believe that EP, like γ-oryzanol, can be developed as a beneficial agent for the prevention and control of NAFLD and associated cardiac dysfunction.
本动物实验旨在评估预发芽糙米提取物(EP)和γ-谷维素对非酒精性脂肪性肝病(NAFLD)及其相关心脏并发症的疗效。将WKY大鼠喂饲高果糖水(HFW)和高脂饮食(HFD)4周以诱导NAFLD。另外两组喂饲HFW和HFD,同时每天口服200μL/kg的EP或2mg/kg的γ-谷维素,持续4周。成功诱导出NAFLD,表现为体重、肝脏和心脏重量明显增加,血压和心率升高,高甘油三酯血症,高尿酸血症,肝功能指标谷丙转氨酶(GPT)升高,血液中白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平升高以及肝脏中甘油三酯(TG)水平升高。NAFLD大鼠在脂质合成、炎症、心脏纤维化和肥大的蛋白质表达方面也有不良变化。然而,当NAFLD大鼠同时喂饲EP或γ-谷维素时,包括谷草转氨酶(GOT)在内的不良饮食诱导效应的发展明显得到改善。具体而言,EP可降低尿酸水平,而γ-谷维素则不能。EP以及γ-谷维素可逆转脂质合成、炎症、心脏纤维化和肥大水平的升高。我们得出结论,EP有效预防了HFW/HFD诱导的NAFLD及其相关心脏并发症,这可能是通过改善脂质稳态和抑制炎症实现的。我们认为,EP与γ-谷维素一样,可开发成为预防和控制NAFLD及相关心脏功能障碍的有益药物。